These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. Cookson JC; Kennedy NM; Gribbon D Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879 [TBL] [Abstract][Full Text] [Related]
28. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses. Roose K Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558 [TBL] [Abstract][Full Text] [Related]
29. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463 [TBL] [Abstract][Full Text] [Related]
30. Haloperidol decanoate in the treatment of schizophrenia. Zapletálek M; Zbytovský J Act Nerv Super (Praha); 1989 Apr; 31(1):39-41. PubMed ID: 2571224 [No Abstract] [Full Text] [Related]
31. Case report: increased patient response to intramuscular haloperidol decanoate following a change in needle length. Brahm NC; Washington NB J Pharm Pract; 2011 Dec; 24(6):561-3. PubMed ID: 22048930 [TBL] [Abstract][Full Text] [Related]
32. [The neuroleptic malignant syndrome (NMS). A report of a clinical case with a protracted and recurrent course. A review of the literature]. Marelli A; Bodini P; Dizioli P; Chiodelli G; Guarneri M; Boldori L Minerva Med; 1996; 87(1-2):45-51. PubMed ID: 8610025 [TBL] [Abstract][Full Text] [Related]
33. Quantitative EEG and BPRS data following Haldol-Decanoate administration in schizophrenics. Schellenberg R; Milch W; Schwarz A; Schober F; Dimpfel W Int Clin Psychopharmacol; 1994; 9(1):17-24. PubMed ID: 7910833 [TBL] [Abstract][Full Text] [Related]
34. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. Sassa T; Suhara T; Ikehira H; Obata T; Girard F; Tanada S; Okubo Y Psychiatry Clin Neurosci; 2002 Dec; 56(6):637-42. PubMed ID: 12485307 [TBL] [Abstract][Full Text] [Related]
35. Side effects during long-term treatment with depot antipsychotic medication. Cookson JC Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940 [TBL] [Abstract][Full Text] [Related]
36. [Rhabdomyolysis and acute renal failure caused by haloperidol-decanoate (neuroleptic malignant syndrome)]. Lazzarin M; Benati F; Cesario V Recenti Prog Med; 1996 Sep; 87(9):422-4. PubMed ID: 9053957 [TBL] [Abstract][Full Text] [Related]
38. [Administration of high dose haloperidol in a patient refractory to treatment with traditional and atypical neuroleptics]. Stip E; Bruneau MA Encephale; 1996; 22(4):298-300. PubMed ID: 9035986 [No Abstract] [Full Text] [Related]
39. [Intraindividual comparison of haloperidol decanoate and oxyprothepine in maintenance therapy in schizophrenic psychoses]. Cesková E; Svestka J; Rysánek R Cesk Psychiatr; 1993 Jan; 89(1):11-4. PubMed ID: 8099534 [TBL] [Abstract][Full Text] [Related]
40. Depot neuroleptics: side effects and safety. Marder SR J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]